Novartis AG (FRA:NOTA)
Germany · Delayed Price · Currency is EUR | Market Cap | 273.74B +26.0% |
| Revenue (ttm) | 50.51B +1.8% |
| Net Income | 8.83B -30.3% |
| EPS | 4.72 -28.3% |
| Shares Out | n/a |
| PE Ratio | 30.28 |
| Forward PE | 16.56 |
| Dividend | 3.45 (2.41%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | n/a |
| Open | 144.00 |
| Previous Close | 144.00 |
| Day's Range | 143.00 - 144.00 |
| 52-Week Range | 105.50 - 146.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 27, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia ... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USD Financial StatementsNews
Novartis Wins Positive CHMP Opinion For Cosentyx In Adolescent Hidradenitis Suppurativa
(RTTNews) - Novartis (NVS, NOVN.SW) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Cosentyx (secukinumab) for adol...
Novartis reports positive CHMP opinion for Cosentyx in adolescents 12 and older
Novartis (NVS) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing authorization of Cosentyx for ad...
Novartis says long-term Rhapsido data show sustained efficacy
Novartis (NVS) announced 52-week results from the Phase III RemIND program evaluating Rhapsido in chronic inducible urticaria. In the long-term analysis from the RemIND study, Rhapsido 25 mg twice dai...
Novartis' Ianalumab Shows Continued Benefits In Two-Year Sjögren's Study
(RTTNews) - Novartis AG (NVS, NOVN.SW) on Tuesday reported encouraging two-year results from its ongoing Phase 3 NEPTUNUS extension study of investigational drug ianalumab, showing further improvement...
Novartis presents long-term results from ongoing NEPTUNUS extension study
Novartis (NVS) presented long-term results from the ongoing NEPTUNUS extension study of ianalumab in Sjogren’s disease at the American College of Rheumatology Convergence 2026. The data showed that th...
How IBD Stock Of The Day TG Therapeutics Is Catching Up To Roche, Novartis
TG Therapeutics is Tuesday's IBD Stock Of The Day. Shares topped a buy zone despite a mixed Q3 report, but are in range of an alternate entry.
Zacks Industry Outlook Highlights Eli Lilly, Novartis and Bayer
LLY, NVS and BAYRY stand out as the pharma sector rebounds in 2026, supported by innovative drug pipelines, strong product demand and rising earnings estimates.
A failed trial for a heart drug casts shadow over rivals developing similar therapies
The full data from the closely watched clinical trial showed that the drug had no cardiovascular benefit even though it reduced Lp(a) levels.
Novartis drops heart drug after it failed to prevent heart attacks
Novartis is ending development of pelacarsen in heart disease. In a study of more than 8,300 patients the drug cut Lp(a) levels by 78% but did not reduce heart attacks or strokes.
Novartis to discontinue development of pelacarsen, Bloomberg says
Novartis (NVS) is discontinuing the development of pelacarsen, a drug that was meant to treat atherosclerotic cardiovascular disease, Fabienne Kinzelmann and Robert Langreth of Bloomberg reports. The ...
Trial failures of Novartis, Novo Nordisk heart drugs leave experts guessing
An experimental Novartis drug designed to treat a genetic cause of heart disease failed to reduce deaths and non-fatal heart attacks, dashing hopes for the first of several such drugs in clinical tria...
Novartis price target raised to CHF 150 from CHF 135 at Citi
Citi raised the firm’s price target on Novartis (NVS) to CHF 150 from CHF 135 and keeps a Buy rating on the shares.
Novartis: 3 Key Takeaways for Long-Term Investors
Novartis raised full-year 2026 core operating income guidance after 4% sales growth. Rhapsido peak sales guidance increased to over $4 billion in combined indications.
BioArtic's BrainTransporter Collaboration With Novartis Ends Following Program Discontinuation
(RTTNews) - BioArctic AB (BIOA B) announced that collaborator Novartis has decided to terminate an option, collaboration and license agreement signed in August 2025 that was aimed at exploring a poten...
BioArctic collaborator Novartis terminates agreement
STOCKHOLM, Nov. 2, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Colla...
6 dividend stocks for investors who want to cut their exposure to the S&P 500
Novartis, Mitsubishi and Canadian Natural are examples of companies in developed markets outside the U.S. that pass screens for high dividend yields and low volatility for prices and earnings.
Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target
The recent failure of a Novartis experimental heart drug in a large trial raised questions among cardiologists and investors about the widely held idea tha
Companies promised AI gains— here's how the payoff showed up in earnings
Companies including Santander, Novartis and Standard Chartered say artificial intelligence is beginning to contribute to revenue, costs or profitability. Santander said AI initiatives generated 194 mi...
Novartis downgraded to Sell at Deutsche Bank on pending exclusivity cliff
As previously reported, Deutsche Bank analyst Emmanuel Papadakis downgraded Novartis (NVS) to Sell from Hold with a price target of CHF 115, down from CHF 120, after what the firm…
Novartis downgraded to Sell from Hold at Deutsche Bank
Deutsche Bank downgraded Novartis (NVS) to Sell from Hold with a price target of CHF 115, down from CHF 120.
A pharma giant is moving past one patent cliff — but another is already looming
Novartis CEO Vas Narasimhan told CNBC on Tuesday that its drug remibrutinib could become "one of our largest medicines in history." But analysts slashed the peak sales forecast for the drug after a la...
Novartis price target raised to CHF 145 from CHF 135 at JPMorgan
JPMorgan raised the firm’s price target on Novartis (NVS) to CHF 145 from CHF 135 and keeps an Overweight rating on the shares.
Novartis price target raised to CHF 130 from CHF 120 at RBC Capital
RBC Capital raised the firm’s price target on Novartis (NVS) to CHF 130 from CHF 120 and keeps a Sector Perform rating on the shares. The company reported solid Q3…
Monte Rosa Therapeutics collaborator Novartis initiates MGD MRT-6160 study
Monte Rosa Therapeutics (GLUE) announced that its collaborator Novartis (NVS) has initiated a second Phase 2 clinical study for the VAV1-directed MGD MRT-6160 in people living with active moderate to…
Novartis price target raised to $163 from $156 at Morgan Stanley
Morgan Stanley analyst Thibault Boutherin raised the firm’s price target on Novartis (NVS) to $163 from $156 and keeps an Overweight rating on the shares. The firm sees upside to…